Aspirin therapy
This article was originally published in The Tan Sheet
Executive Summary
Daily doses of 75 mg-150 mg per day reduce risk of vascular events by 32% in high-risk patients, according to meta-analysis by Antithrombotic Trialists' Collaboration (Oxford, England) in Jan. 12 British Medical Journal. C. Baigent, et al., reviewed a total of 287 studies involving 212,000 patients that compared antiplatelet therapy with either controls or other antiplatelet regimens. Accompanying editorial by John Cleland, University of Hull, maintains aspirin efficacy is overstated since it does not reduce mortality...
You may also be interested in...
Aspirin Therapy Mortality Reduction Confirmation Urged In BMJ Editorial
A "definitively positive trial" on aspirin's effectiveness at lowering mortality due to coronary heart disease is still needed, John Cleland, University of Hull, UK, states in an editorial in the Jan. 12 British Medical Journal
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.